Report ID: SQSG35I2039 | Region: Global | Published Date: September, 2022 | Pages: 157 | Tables: 61 | Figures: 65Global Pharmerging Market
Report ID: SQSG35I2036 | Region: Global | Published Date: September, 2022 | Pages: 157 | Tables: 63 | Figures: 65
Global duchenne muscular dystrophy market was valued at USD 693.34 million in 2021, and it is expected to reach a value of USD 1533.72 million by 2028, at a CAGR of more than 11.87% over the forecast period (2022–2028).
Duchenne muscular dystrophy is an illness in which muscular weakness happens. Muscle weakness is a defining feature of this hereditary condition. This rare illness primarily affects males. This illness results in mental retardation, respiratory failure, pneumonia, heart failure, muscle weakness, and intellectual incapacity. With the help of this diagnostic care, people with Duchenne muscular dystrophy can receive precise and effective treatment. This sort of diagnostic therapy lessens or manages symptoms but does not provide a cure. In addition to stem cell therapy and gene therapy, medications like steroids are used to treat Duchenne muscular dystrophy and lessen its symptoms.
In the case of DMD, a characteristic of this inherited illness is muscle weakness. Males are the main victims of this rare disease. Mental retardation, pneumonia, heart failure, respiratory failure, muscle weakness, and intellectual disability are all side effects of this condition. People with Duchenne muscular dystrophy can get precise and efficient treatment with the use of this diagnostic care. While not offering a cure, this type of diagnostic therapy lowers or manages symptoms. Drugs like steroids are used to treat Duchenne muscular dystrophy and decrease its symptoms in addition to stem cell therapy and gene therapy.
Global duchenne muscular dystrophy market is anticipated to rise as R&D spending increases to create possible treatments for DMD. For instance, the Muscular Dystrophy Association (MDA), United States, funded $75,000 in research and development to create a DMD treatment. More than 150 hospitals, healthcare facilities, and care facilities in the United States and other nations have received grants from the group.
Additionally, factors like ongoing research into gene and stem cell therapy and exon skipping drugs for DMD treatment are projected to drive global duchenne muscular dystrophy market.
To get more reports on the above market click here to Buy The Report
Global duchenne muscular dystrophy market is segmented based on distribution channel, therapy, and region. On the basis of therapy, the market is segmented into mutation suppression, exon skipping approach, others therapies. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on region it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.
Analysis by Therapy
On the basis of therapy, the market is segmented into mutation suppression, exon skipping approach, others therapies. Among these the segment of Exon Skipping Approach held the largest share as the segment has grown due to result of EXONDYS 51 becoming more widely used. Exon 51 can be skipped to treat individuals with a proven hereditary mutation in the dystrophin gene, making EXONDYS 51 the first Duchenne muscular dystrophy medication that the FDA has approved. In some patients, it aids in the body's production of a cut-down form of the dystrophin protein. The dystrophin gene, which encodes a protein crucial for preserving the integrity of the membrane of muscle cells, is primarily responsible for Duchenne muscular dystrophy. To allow the remaining exons to come together, one prospective therapeutic strategy is to mask an exon near to the location where the others are missing. Exon-skipping therapy is one of the most effective methods for restoring the expression of a shorter but functional dystrophin protein.
Analysis by Distribution Channel
On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment to grow at faster rate. The Duchenne muscular dystrophy market includes the introduction of novel medications and treatments, substantial funding from numerous companies for drug development, disease-modifying treatments, and assistance from patient advocacy groups for the regulatory approval procedure. The expansion of the global market is projected to be fueled by an increase in the number of clinical trials exploring potential treatments for Duchenne muscular dystrophy and a robust product pipeline. Duchenne muscular dystrophy treatment is predicted to advance with the development of mutation-specific medicines. Duchenne muscular dystrophy's rising disease burden, rising pharmaceutical research and development expenditures to produce innovative disease therapies, and rising DMD awareness campaigns all contribute to the market's expansion.
To get detailed analysis on other segments, Request For Sample Report
North America dominated the global duchenne muscular dystrophy market. The market in North America is expected to expand as a result of a number of important factors, including the rising prevalence of muscular dystrophy in the region, FDA drug approval, strong healthcare infrastructure supported by supportive government regulations, and medical reimbursement in the region and due to anticipated product launches.
Asia Pacific market is expected to hold the second largest share of global market. On the back of the region's high prevalence of musculoskeletal illnesses and large male population. In India, for example, 51.96% of the population would be male, according to the World Bank. In addition, it is expected that the market will rise due to the ongoing improvement of public healthcare services and strong economic expansion. The pharmaceutical firms in the region are relocating clinical trial operations to new trial areas, which are primarily low- and middle-income countries. Additionally, the region's high frequency of the target condition is anticipated to fuel regional market expansion.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report
Global duchenne muscular dystrophy market is competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D.
Top Players in the Global Duchenne Muscular Dystrophy Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.
According to our analysis, North America dominated the global market attributed to rising prevalence of muscular dystrophy in the region, FDA drug approval, strong healthcare infrastructure supported by supportive government regulations, and medical reimbursement in the region and due to anticipated product launches. Among these the segment of Exon Skipping Approach held the largest share as the segment has grown due to result of EXONDYS 51 becoming more widely used. Based on distribution channel, the hospital pharmacy segment to grow at faster rate. The Duchenne muscular dystrophy market includes the introduction of novel medications and treatments, substantial funding from numerous companies for drug development, disease-modifying treatments, and assistance from patient advocacy groups for the regulatory approval procedure
|Market size value in 2021||USD 693.34 million|
|Market size value in 2028||USD 1533.72 million|
|Growth Rate||more than 11.87%|
|Forecast Unit (Value)||USD Million|
|Regions covered||North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)|
Free report customization with purchase. Customization includes:-
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Parent Market Analysis
KEY MARKET INSIGHTS
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global Duchenne Muscular Dystrophy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Duchenne Muscular Dystrophy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Duchenne Muscular Dystrophy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Duchenne Muscular Dystrophy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "
- Mr. Ali Zali, Commercial Director, ICIIC Iran.